Stocks
Cassava Sciences, Inc.SAVA
NASDAQHealthcareBiotechnology$2.09-12.18%
A clinical-stage biotechnology company focused on developing therapies for neurodegenerative diseases, particularly Alzheimer’s disease. Its lead drug candidate, simufilam, has been the subject of clinical trials and regulatory scrutiny, drawing significant attention from both biotech investors and ...
Market Cap: $101.0M52W Range: $1.15 – $4.98
Congressional Interest in Cassava Sciences, Inc. (SAVA)
1 member of Congress has disclosed 5 trades in Cassava Sciences, Inc. (SAVA), a Healthcare company. The buy/sell breakdown shows 3 purchases versus 2 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
5
Unique Politicians
1
Buys
3
Sells
2
Who in Congress Is Trading SAVA?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2022-12-12 | Christopher L. Jacobs | buy | $1K – $15K |
| 2022-11-08 | Christopher L. Jacobs | sell | $1K – $15K |